Biogen has entered into a definitive agreement to acquire Human Immunology Biosciences (HI-BIO) for an upfront payment of $1.15 billion and up to an additional $650 million in milestone payments, bringing the potential total deal value to $1.8 billion. Human Immunology Biosciences, which was incubated by ARCH Venture Partners and Monograph Capital, specializes in developing precision therapies for immune-mediated diseases. The deal, advised by the Life Sciences team at Goodwin, is expected to close in the third quarter of 2024 subject to regulatory approvals. Notably, the acquisition is not anticipated to impact Biogen’s 2024 financial guidance, and the company intends to finance the purchase with cash and potentially its revolving credit agreement. HI-Bio’s lead asset, felzartamab, is pivotal to the acquisition strategy, showing promise in clinical studies for treating various immune-mediated diseases. Goodwin’s legal advisory team for the transaction included experts in corporate, intellectual property, compensation and benefits, tax, regulatory, privacy and data security, labor and employment, and antitrust law.

Biotechnology, Pharmaceuticals, Private Equity & Venture Capital,United States